Mirikizumab,
does it really help with Week-12 clinical remission in moderate-to-severe ulcerative colitis?
research showsGrade C. Week-12 remission was 210/868 (24.2%) versus 39/294 (13.3%), an absolute difference of 11.1 points (99.875% CI 3.2 to 19.1).
ads claimThe composite combines patient symptoms (stool frequency and rectal bleeding) with endoscopic findings, but does not directly measure colectomy, hospitalization, or death.
Useful facts when choosing a product
- Targets IL-23 p19.
- LUCENT-1 was a 12-week induction trial.
- Infections require attention.
What the research actually shows
Four gates: no listed defect was identified. Axis 6 B0 evidence ① Allocation concealment: "randomly assigned in a 3:1 ratio" through an interactive web-response system. ② Blinding: "double-blind, placebo-controlled". ③ Analysis and missingness: "modified intention-to-treat population" with nonresponder imputation. ④ Prespecified primary endpoint: "clinical remission at week 12" - consistent with NCT03518086
Why this is classified as C (54)
Positive, well-conducted evidence uses a composite of patient symptoms and endoscopic findings rather than a hard endpoint; one trial and sole Eli Lilly sponsorship give C, 54.
Counterpoint. Maintenance and long-term clinical events are separate questions.
Rejudgment record. Axes and scorer agree — LUCENT-1 week-12 clinical remission
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Week-12 clinical remission | C | Rates were 24.2% versus 13.3%. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Phase 3 double-blind placebo-controlled randomized induction trial | 294 | Funded and analyzed by Eli Lilly | Composite clinical remission at week 12 | 210/868 (24.2%) vs 39/294 (13.3%); difference 11.1 points (99.875% CI 3.2 to 19.1) | Pivotal induction evidence |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] Benefit of Mirikizumab for 12-Week Clinical Remission in Moderate-to-Severe Ulcerative Colitis — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/mirikizumab-ulcerative-colitis-week12-remission/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.